Sector pending / Drug Stores and Proprietary StoresUpdated 2026-05-10 22:07 UTC

KLSE/PHARMA stock hub

KLSE/PHARMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KLSE/PHARMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.6B

Bursa Malaysia

Market data

Live price

Current market quote for this ticker.

Current price

KLSE/PHARMA

In the news

Latest news · KLSE/PHARMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E15

P25 n/aP50 n/aP75 n/a

Trailing P/E17.9

P25 n/aP50 n/aP75 n/a

ROE32.4

P25 n/aP50 n/aP75 n/a

ROIC8.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KLSE/PHARMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

212

Groups with data

Currency

MYR

Showing 212 of 212 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Malaysia
Country code	MY
Employees	3,502
Employees Change	26%
Employees Change Percent	0.75
Enterprise value	MYR 2.1B
Exchange	Bursa Malaysia
Financial currency	MYR
First seen	2026-05-10
Industry	Drug Stores and Proprietary Stores
Last refreshed	2026-05-10
Market cap	MYR 1.6B
Price	MYR 0.24
Price currency	MYR
Rev Per Employee	1,121,574.24x
Sic	5912
Symbol	klse/PHARMA
Website	https://www.pharmaniaga.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.08%
EV Earnings	44.13x
EV/EBIT	16.51x
EV/EBITDA	12.98x
EV/FCF	-45.09x
EV/Sales	0.54x
FCF yield	-3.02%
Forward P/E	15x
P/B ratio	3.43x
P/E ratio	17.91x
P/S ratio	0.4x
PE Ratio10 Y	19.9x
PE Ratio5 Y	15.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	3.3%
EBITDA Margin	3.93%
Gross margin	10.42%
Gross Profit	MYR 409.2M
Gross Profit Growth	-24.3%
Gross Profit Growth Q	-8.63%
Gross Profit Growth3 Y	6.08%
Gross Profit Growth5 Y	6.75%
Net Income	MYR 48.5M
Net Income Growth	-63.2%
Net Income Growth Q	227.87%
Net Income Growth5 Y	12.03%
Pretax Margin	1.9%
Profit Margin	1.24%
Profit Per Employee	MYR 13,852
ROA	3.82
Roa5y	4.47
ROCE	20.39
ROE	32.36
ROIC	8.37
Roic5y	9.46

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-6.54%
Cagr15y	3%
Cagr1y	58.37%
Cagr20y	4.07%
Cagr3y	4.38%
Cagr5y	-7.76%
Div CAGR10	2.48%
Div CAGR5	30.83%
EPS Growth	-85.35
EPS Growth Q	27.83
EPS Growth5 Y	-8.59
FCF Growth Q	-8.57%
OCF Growth Q	-8.09%
Revenue Growth	4.48x
Revenue Growth Q	1.28x
Revenue Growth3 Y	4.11x
Revenue Growth5 Y	7.59x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	MYR 1.85
Assets	MYR 2.2B
Cash	MYR 277.6M
Current Assets	MYR 1.5B
Current Liabilities	MYR 1.6B
Debt	MYR 819.8M
Debt EBITDA	MYR 4.97
Debt Equity	MYR 1.79
Debt FCF	MYR -17.27
Equity	MYR 459.2M
Interest Coverage	2.11
Liabilities	MYR 1.8B
Long Term Assets	MYR 782.6M
Long Term Liabilities	MYR 176.6M
Net Cash	MYR -542.2M
Net Cash By Market Cap	MYR -34.46
Net Debt EBITDA	MYR 3.51
Net Debt Equity	MYR 1.18
Tangible Book Value	MYR 334.8M
Tangible Book Value Per Share	MYR 0.05
WACC	7.65

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.91
Inventory Turnover	5.24
Net Working Capital	MYR 269.6M
Quick ratio	0.43
Working Capital	MYR -146.8M
Working Capital Turnover	MYR -8.77

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-150.74%
Dividend per share	MYR 0
Last Dividend	MYR 0.01

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-49.15%
1Y total return	58.32%
200-day SMA	0.25
3Y total return	13.72%
50-day SMA	0.25
50-day SMA vs 200-day SMA	50over200
5Y total return	-33.21%
All Time High	1.51
All Time High Change	-84.06%
All Time High Date	2015-04-28
All Time Low	0.03
All Time Low Change	826.64%
All Time Low Date	1999-11-18
ATR	0.01
Beta	0.86
Beta1y	1.25
Beta2y	0.78
Ch YTD	-15.79
High	0.25
High52	0.34
High52 Date	2026-02-04
High52ch	-29.41%
Low	0.24
Low52	0.13
Low52 Date	2025-07-01
Low52ch	84.62%
Ma50ch	-5.03%
Price vs 200-day SMA	-3.81%
RSI	39.56
RSI Monthly	42.13
RSI Weekly	43.11
Sharpe ratio	0.83x
Sortino ratio	1.64
Total Return	-150.74%
Tr YTD	-15.79
Tr15y	55.79%
Tr1m	-4%
Tr3m	-18.64%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	MYR 129.6M
Operating Income Growth	-50.31
Operating Income Growth Q	-22.69
Operating Income Growth3 Y	66.67
Operating Income Growth5 Y	13.91
Operating margin	3.3

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,305,233,459%
Net Borrowing	-349,548,000
Shares Insiders	2.73%
Shares Institutions	11.39%
Shares Out	6,557,025,388
Shares Qo Q	37.83%
Shares Yo Y	150.74%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	MYR -47.5M
Average Volume	7,932,895x
Bv Per Share	0.07
CAPEX	MYR -29.8M
Ch10y	-78.38
Ch15y	-48.14
Ch1m	-4
Ch1y	-5.88
Ch20y	-43.06
Ch3m	-18.64
Ch3y	-32.39
Ch5y	-65.52
Ch6m	-9.43
Change	0%
Change From Open	0
Close	0.24
Days Gap	0
Depreciation Amortization	24,643,000
Dollar Volume	1,979,688
Earnings Date	2026-05-15
EBIT	MYR 129.6M
EBITDA	MYR 154.3M
EPS	MYR 0.01
F Score	4
FCF	MYR -47.5M
FCF EV Yield	-2.22x
FCF Per Share	MYR -0.01
Financing CF	164,621,000
Fiscal Year End	December
Founded	1,994
Goodwill	77,028,000
Graham Number	0.14134
Graham Upside	-41.11
Income Tax	MYR 24.1M
Investing CF	-180,238,000
Is Primary Listing	1
Last Earnings Date	2026-02-27
Last Report Date	2025-12-31
Last Split Date	2021-07-05
Last Split Type	Forward
Lynch Fair Value	MYR 0.16
Lynch Upside	-32.84
Ma150	0.27
Ma150ch	-9.54%
Ma20	0.24
Ma20ch	-1.03%
Net CF	-35,485,000
Next Earnings Date	2026-05-15
Open	0.24
Position In Range	50
Ppne	602,779,000
Price Date	2026-05-08
Price EBITDA	MYR 10.2
Ptbv Ratio	4.7
Relative Volume	1.04x
Revenue	3,927,753,000x
Tax By Revenue	0.61x
Tax Rate	32.18%
Tr20y	121.86%
Tr6m	-9.43%
Volume	8,248,700
Z Score	2.22

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KLSE/PHARMA pay a dividend?

Capital-return profile for this ticker.

Performance

KLSE/PHARMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KLSE/PHARMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+11.4%

Share of float held by funds and institutions

Insider ownership

+2.7%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+150.7%

Negative means the company is buying back shares.

Technical

KLSE/PHARMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

39.6

Neutral momentum band

Price vs 200-day MA

-3.8%

50/200-day relationship not available

Beta (5Y)

0.86

Moves roughly with the market

Sharpe ratio

0.83

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KLSE/PHARMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current klse/PHARMA stock rating?

klse/PHARMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full klse/PHARMA analysis?

The full report lives at /stocks/klse/PHARMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for klse/PHARMA?

The latest report frames klse/PHARMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the klse/PHARMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.